GleamWall
中文EN

PEN Penumbra Inc

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1321732 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.0%
TTM net income YoY-4.3%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR16.2%
Net income 3-yr CAGR56.9%

Margins

Gross margin68.0%
Operating margin12.1%
Net margin10.1%
FCF margin12.8%
EBITDA margin13.4%

Returns

ROE10.7%
ROA8.3%
ROIC (approx.)12.1%
Asset turnover0.83x

Leverage & solvency

Liabilities / assets21.8%
Debt / equity0.00x
Current ratio5.89x
Interest coverage149.48x

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$410.14M$390.05M$374.76M$385.38M$354.69M$339.45M$324.14M$315.52M
Cost of revenue$129.84M$125.10M$121.35M$123.26M$114.27M$115.44M$108.26M$104.80M
Gross profit$280.30M$264.94M$253.41M$262.13M$240.42M$224.01M$215.88M$210.72M
R&D expense$25.36M$25.40M$22.38M$21.79M$22.68M$23.22M$22.08M$20.01M
SG&A expense$204.20M$198.51M$192.79M$181.10M$168.90M$159.96M$153.46M$147.94M
Operating income$50.74M$41.04M$38.23M$59.23M$48.84M$40.83M$40.35M$42.77M
Interest expense$305,000$311,000$317,000$333,000$338,000$319,000$322,000$337,000
Pretax income$56.32M$46.19M$41.69M$63.63M$52.33M$45.31M$43.86M$44.34M
Income tax$14.04M$11.38M$9.10M$16.29M$6.47M$40,000$4.63M$10.66M
Net income$42.28M$34.81M$32.58M$47.34M$45.85M$45.27M$39.22M$33.68M
EBITDA$56.20M$46.65M$42.81M$63.69M$51.33M$46.34M$45.37M$47.16M
EPS (basic)1.070.880.83—1.171.171.02—
EPS (diluted)1.070.880.82—1.171.151.00—
Weighted avg. shares (diluted)39.62M39.57M39.54M—39.30M39.25M39.16M—
Balance sheet
Cash & equivalents$254.28M$205.27M$241.29M$186.90M$321.03M$421.77M$376.05M$324.40M
Short-term investments$419.33M$453.52M$374.37M$357.92M$149.27M$2.79M$2.79M$15.73M
Receivables$195.22M$190.41M$183.29M$190.02M$183.43M$175.54M$167.98M$167.67M
Inventory$459.13M$442.65M$438.54M$431.55M$432.37M$427.63M$415.86M$406.74M
Current assets$1.38B$1.34B$1.28B$1.22B$1.14B$1.07B$999.71M$951.12M
PP&E, net$156.44M$146.72M$134.06M$117.44M$97.73M$84.83M$72.47M$62.64M
Goodwill$166.48M$166.52M$166.59M$166.75M$166.75M$166.75M$166.12M$165.83M
Intangibles$5.55M$5.74M$5.95M$6.19M$6.37M$6.55M$6.47M$6.51M
Total assets$2.03B$1.97B$1.90B$1.83B$1.74B$1.67B$1.59B$1.53B
Current liabilities$233.81M$233.78M$211.73M$183.13M$169.60M$157.76M$158.63M$158.34M
Total liabilities$441.59M$443.96M$424.63M$398.92M$385.67M$380.86M$380.43M$382.25M
Shareholders' equity$1.58B$1.53B$1.47B$1.43B$1.36B$1.29B$1.21B$1.15B
Shares outstanding———39.23M———38.49M
Cash flow statement
Operating cash flow$41.51M$46.08M$86.97M$86.48M$58.26M$44.95M$48.97M$51.11M
Capital expenditure$15.11M$13.54M$13.67M$18.43M$16.25M$15.58M$13.47M$5.37M
Free cash flow$26.40M$32.54M$73.30M$68.05M$42.01M$29.37M$35.50M$45.74M
Investing cash flow$8.68M-$91.09M-$30.63M-$225.65M-$162.86M-$15.58M-$502,000-$10.96M
Financing cash flow-$1.06M$9.03M-$1.91M$5.06M$3.95M$14.82M$2.71M$6.07M
Depreciation & amortization$5.47M$5.62M$4.57M$4.46M$2.49M$5.51M$5.01M$4.39M
Stock-based compensation$14.83M$13.66M$14.64M$15.26M$15.93M$14.23M$13.79M$12.10M
Share buybacks———$0———-$1,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.